Positive News SentimentPositive NewsNASDAQ:NEPH Nephros (NEPH) Stock Price, News & Analysis $4.03 -0.02 (-0.49%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$4.12 +0.09 (+2.11%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nephros Stock (NASDAQ:NEPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nephros alerts:Sign Up Key Stats Today's Range$4.02▼$4.2050-Day Range$2.89▼$5.0052-Week Range$1.36▼$5.00Volume5,889 shsAverage Volume55,150 shsMarket Capitalization$42.72 millionP/E Ratio33.58Dividend YieldN/APrice Target$5.50Consensus RatingBuy Company Overview Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Read More Nephros Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreNEPH MarketRank™: Nephros scored higher than 47% of companies evaluated by MarketBeat, and ranked 617th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNephros has only been the subject of 1 research reports in the past 90 days.Read more about Nephros' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nephros is 33.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Nephros is 33.58, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.26.Price to Book Value per Share RatioNephros has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nephros' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of Nephros has been sold short.Short Interest Ratio / Days to CoverNephros has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nephros has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNephros does not currently pay a dividend.Dividend GrowthNephros does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.05% of the float of Nephros has been sold short.Short Interest Ratio / Days to CoverNephros has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nephros has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentNephros has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nephros this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nephros insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Nephros is held by insiders.Percentage Held by Institutions41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nephros' insider trading history. Receive NEPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEPH Stock News HeadlinesNephros Second Quarter 2025 Earnings: Beats ExpectationsAugust 10, 2025 | finance.yahoo.comNephros Inc (NEPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Profitability ...August 9, 2025 | finance.yahoo.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 29 at 2:00 AM | The Oxford Club (Ad)Nephros Announces Strong Second Quarter Financial ResultsAugust 7, 2025 | globenewswire.comNephros Schedules Second Quarter 2025 Financial Results Conference CallJuly 31, 2025 | globenewswire.comNephros Inc. (NEPH) Stock Price Today - WSJJuly 4, 2025 | wsj.comJune 2025's Promising Penny Stocks With Growth PotentialJune 23, 2025 | finance.yahoo.comNephros, Inc. (NASDAQ:NEPH) Shares Could Be 37% Below Their Intrinsic Value EstimateJune 23, 2025 | uk.finance.yahoo.comSee More Headlines NEPH Stock Analysis - Frequently Asked Questions How have NEPH shares performed this year? Nephros' stock was trading at $1.47 at the start of the year. Since then, NEPH shares have increased by 174.1% and is now trading at $4.03. How were Nephros' earnings last quarter? Nephros Inc. (NASDAQ:NEPH) issued its quarterly earnings results on Thursday, August, 7th. The company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The business had revenue of $4.40 million for the quarter, compared to analyst estimates of $3.60 million. Nephros had a net margin of 7.95% and a trailing twelve-month return on equity of 14.89%. Read the conference call transcript. Who are Nephros' major shareholders? Nephros' top institutional investors include Topline Capital Management LLC (4.50%), Geode Capital Management LLC (0.88%) and Elkhorn Partners Limited Partnership (0.14%). Insiders that own company stock include Arthur H Amron and Robert R Jr Banks. View institutional ownership trends. How do I buy shares of Nephros? Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nephros own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/07/2025Today8/28/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NEPH CIK1196298 Webwww.nephros.com Phone(201) 343-5202Fax201-343-5207Employees30Year FoundedN/APrice Target and Rating Average Price Target for Nephros$5.50 High Price Target$6.00 Low Price Target$5.00 Potential Upside/Downside+36.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.12 Trailing P/E Ratio33.58 Forward P/E RatioN/A P/E GrowthN/ANet Income$70 thousand Net Margins7.95% Pretax Margin8.10% Return on Equity14.89% Return on Assets11.64% Debt Debt-to-Equity RatioN/A Current Ratio5.41 Quick Ratio4.14 Sales & Book Value Annual Sales$14.16 million Price / Sales3.02 Cash Flow$0.02 per share Price / Cash Flow202.39 Book Value$0.91 per share Price / Book4.43Miscellaneous Outstanding Shares10,600,000Free Float9,891,000Market Cap$42.72 million OptionableNot Optionable Beta1.11 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:NEPH) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.